openPR Logo
Press release

Neuroendocrine Tumors Pipeline Report 2024 | Clinical Trials, FDA, EMA, PMDA Approvals

06-15-2024 03:00 AM CET | Health & Medicine

Press release from: ABNewswire

Neuroendocrine Tumors Pipeline Report 2024 | Clinical Trials,

DelveInsight's, "Neuroendocrine Tumors Pipeline Insight 2024" report provides comprehensive insights about 115+ companies and 130+ pipeline drugs in Neuroendocrine Tumors pipeline landscape. It covers the Neuroendocrine Tumors pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Neuroendocrine Tumors therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore our latest breakthroughs in Neuroendocrine Tumors research. Learn more about our innovative pipeline today! @ Neuroendocrine Tumors Pipeline Outlook [https://www.delveinsight.com/sample-request/neuroendocrine-tumors-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the Neuroendocrine Tumors Pipeline Report

* June 2024:- ITM Solucin GmbH - The purpose of the study is to evaluate the efficacy, safety & patient-reported outcomes of peptide receptor radionuclide therapy (PRRT) with 177Lu-Edotreotide as 1st or 2nd line of treatment compared to best standard of care in patients with well-differentiated aggressive grade 2 and grade 3, somatostatin receptor-positive (SSTR+), neuroendocrine tumours of gastroenteric or pancreatic origin.
* June 2024:- Washington University School of Medicine - High grade neuroendocrine neoplasm patients are treated with platinum doublets such as carboplatin and etoposide mimicking the current guidelines for small cell lung cancer (SCLC). Unfortunately, recurrences are common and most patients with metastatic disease succumb to it within a year.
* June 2024:- Advanced Accelerator Applications - This is a multicenter, open-label, single-arm study to evaluate the safety and dosimetry of Lutathera in adolescent patients 12 to
* June 2024:- Suzhou Zelgen Biopharmaceuticals Co.,Ltd - A Phase I/II Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of ZG005 in Combination With Etoposide and Cisplatin in Participants With Advanced Neuroendocrine Carcinoma.
* DelveInsight's Neuroendocrine Tumors pipeline report depicts a robust space with 115+ active players working to develop 130+ pipeline therapies for Neuroendocrine Tumors treatment.
* The leading Neuroendocrine Tumors Companies such as Ipsen, Shenzhen Chipscreen Biosciences Co., Ltd., Hutchison Medipharma Limited, RayzeBio Inc., Amgen, Camurus, BeiGene, EpicentRx, GlaxoSmithKline, Crinetics Pharmaceuticals, Eli Lilly and Company, Seneca Therapeutics, ADC Therapeutics, Vyriad, Inc., and others.
* Promising Neuroendocrine Tumors Therapies such as 177Lu-Dotatate, Nivolumab, AlphaMedix, Lutetium [177Lu] Oxodotreotide Injection, Octreotide LAR, and others.

Stay informed about the cutting-edge advancements in Neuroendocrine Tumors Treatments. Download for updates and be a part of the revolution in cancer care @ Neuroendocrine Tumors Clinical Trials Assessment [https://www.delveinsight.com/sample-request/neuroendocrine-tumors-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Neuroendocrine Tumors Emerging Drugs Profile

* RYZ101: RayzeBio, Inc.

RYZ101 is an investigational, targeted RPT designed to deliver a highly potent alpha-emitting radioisotope, Actinium-225 (Ac225), to solid tumors expressing SSTR2. RYZ101 leverages DOTATATE, a known binder and linker used in other radiopharmaceutical produts. RYZ101 uses Ac225 instead of the Lu177 used in Lutathera and thus delivers hundreds of times more potency in cancer cell killing. The higher potency of RYZ101 can provide significant clinical benefit to patients. RYZ101 utilizes a proprietary and patent protected formulation. The drug is being developed for gastroenteropancreatic neuroendocrine tumor, pancreatic net, neuroendocrine tumors, extensive stage small cell lung cancer (ES-SCLC), and other tumors.

* SVV-001: Seneca Therapeutics

SVV-001, an oncolytic virus of the genus Seneca in the Picornaviridae family. SVV-001 is characterized by its ability to replicate selectively in certain human tumor cells ("SVV-permissive cells"), namely those that express TEM8, the receptor of SVV. SVV-001 is non-pathogenic in humans and animals. SVV-001 and the Seneca genus was originally discovered in 2001 at Novartis Pharmaceuticals by Dr. Paul Hallenbeck. SVV-001 was further developed as a novel cancer therapeutic at Neotropix, Inc. SVV-001 has been extensively tested in over 30 non-clinical cancer models, including immunotherapeutic settings, and in three clinical trials for various solid cancer namely neuroendocrine tumors such as carcinoids, small cell lung cancer and a variety of pediatric cancers. These trials confirmed the safety of intravenous dosing of SVV-001 and safety along with suggestions of significant clinical benefit. Currently the drug is in Phase II stage of Clinical trial evaluation for the treatment of Neuroendocrine Tumors.

* Voyager-V1: Vyriad, Inc.

VSV-IFN-NIS (Voyager V1; VV1) is derived from VSV, a bullet-shaped, negative-sense RNA virus with low human seroprevalence; it is engineered to replicate selectively in and kill human cancer cells. VV1 encodes hIFN to increase antitumoral immune response and tumor specificity, plus the thyroidal sodium iodide symporter NIS to allow imaging of virus. VV1 is synergistic with different anti-PD-(L)1 antibodies in several tumor models. Currently the drug is in Phase I/II stage of Clinical trial evaluation for the treatment of Neuroendocrine Tumors.

* ADCT-701: ADC Therapeutics

ADCT-701 is an ADC composed of a humanized IgG1 antibody against human DLK-1, site-specifically conjugated using Glycoconnect technology to PL1601, which contains a valine-alanine cleavable linker and the PBD dimer cytotoxin SG3199. In vitro, ADCT-701 demonstrated potent cytotoxicity in a panel of human cancer cell lines of different origin and levels of DLK-1, while its potency was strongly reduced in DLK-1-negative cell lines. In vivo, ADCT-701 showed potent anti-tumor activity in the DLK1-expressing neuroblastoma-derived SK-N-FI xenograft in which a single dose of ADCT-701 at 0.5 or 1 mg/kg showed dose-dependent anti-tumor activity compared to the vehicle- and isotype control ADC-treated mice. Currently the drug is in Phase I stage of Clinical trial evaluation for the treatment of Neuroendocrine Tumors.

Learn more about Neuroendocrine Tumors Drugs opportunities in our groundbreaking metastatic prostate cancer research and development projects @ Neuroendocrine Tumors Unmet Needs [https://www.delveinsight.com/sample-request/neuroendocrine-tumors-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Neuroendocrine Tumors Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration

* Intravenous
* Subcutaneous
* Oral
* Intramuscular

Neuroendocrine Tumors Products have been categorized under various Molecule types such as

* Monoclonal antibody
* Small molecule
* Peptide

Discover the latest advancements in Neuroendocrine Tumors treatment by visiting our website. Stay informed about how we're transforming the future of oncology @ Neuroendocrine Tumors Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/neuroendocrine-tumors-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the Neuroendocrine Tumors Pipeline Report

* Coverage- Global
* Neuroendocrine Tumors Companies- Ipsen, Shenzhen Chipscreen Biosciences Co., Ltd., Hutchison Medipharma Limited, RayzeBio Inc., Amgen, Camurus, BeiGene, EpicentRx, GlaxoSmithKline, Crinetics Pharmaceuticals, Eli Lilly and Company, Seneca Therapeutics, ADC Therapeutics, Vyriad, Inc., and others.
* Neuroendocrine Tumors Therapies- 177Lu-Dotatate, Nivolumab, AlphaMedix, Lutetium [177Lu] Oxodotreotide Injection, Octreotide LAR, and others.
* Neuroendocrine Tumors Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Neuroendocrine Tumors Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For a detailed overview of our latest research findings and future plans, read the full details of Neuroendocrine Tumors pipeline on our website @ Neuroendocrine Tumors Emerging Drugs and Companies [https://www.delveinsight.com/sample-request/neuroendocrine-tumors-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Content

* Introduction
* Executive Summary
* Neuroendocrine Tumors: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Neuroendocrine Tumors- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* RYZ101: RayzeBio, Inc.
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* SVV-001: Seneca Therapeutics
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* ADCT-701: ADC Therapeutics
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Product Name: Company Name
* Drug profiles in the detailed report.....
* Inactive Products
* Neuroendocrine Tumors Key Companies
* Neuroendocrine Tumors Key Products
* Neuroendocrine Tumors- Unmet Needs
* Neuroendocrine Tumors- Market Drivers and Barriers
* Neuroendocrine Tumors- Future Perspectives and Conclusion
* Neuroendocrine Tumors Analyst Views
* Neuroendocrine Tumors Key Companies
* Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=neuroendocrine-tumors-pipeline-report-2024-clinical-trials-fda-ema-pmda-approvals]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/



This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Neuroendocrine Tumors Pipeline Report 2024 | Clinical Trials, FDA, EMA, PMDA Approvals here

News-ID: 3540061 • Views:

More Releases from ABNewswire

Lemmo's Pizzeria Hosts 14th Annual Golf Tournament to Support Moorpark High School Athletics
Lemmo's Pizzeria Hosts 14th Annual Golf Tournament to Support Moorpark High Scho …
Moorpark, CA - Lemmo's [lemmospizzeria.com]Pizzeria [lemmospizzeria.com] is proud to announce its 14th Annual Golf Tournament, set to take place on September 27th, 2024, at the prestigious Moorpark Country Club. This exciting event invites families, golfers, and local businesses to join in a day of fun and competition, all for a great cause. The tournament's proceeds will directly benefit Moorpark High School Athletics, providing essential funding to support the school's sports programs.
Another Victory for Actelis Networks (NASDAQ: ASNS): $150K+ Order for Multi-Billion Dollar Tier-1 Military Contractor
Another Victory for Actelis Networks (NASDAQ: ASNS): $150K+ Order for Multi-Bill …
Actelis Networks has secured a $150K+ order for a top-tier military contractor. This win follows recent important certifications and a string of contracts across transportation, airports, and utilities. Actelis' momentum across diverse markets, particularly in high-security sectors, suggests potential for significant growth and increased market share in the expanding IoT landscape. In today's digital landscape, where robust cybersecurity and swift implementation of networking solutions are critical, Actelis Networks, Inc. (NASDAQ: ASNS)
Stonegate Firm is a Leading Advocacy Firm for Consumers Who Want to Cancel their Timeshares
Stonegate Firm is a Leading Advocacy Firm for Consumers Who Want to Cancel their …
TULSA, OK - Stonegate Firm [https://stonegatefirm.com/], a premier timeshare exit company, is proud to announce its leadership role in advocating for consumers who wish to cancel their timeshares [https://stonegatefirm.com/timeshare-exit/]. By providing expert assistance and guidance through the often complex and confusing process of timeshare cancellation, Stonegate Firm has positioned itself as a trusted ally for those seeking to escape the financial commitments associated with timeshare ownership. "At Stonegate Firm, we understand the
Atlanta Estate Planning Attorney Trace Brooks Releases New Article About Revocable Living Trusts
Atlanta Estate Planning Attorney Trace Brooks Releases New Article About Revocab …
Atlanta estate planning attorney Trace Brooks (https://www.tracebrookslaw.com/do-i-need-a-revocable-living-trust/), founder of Trace Brooks Law, has published a comprehensive article titled "Do I Need A Revocable Living Trust?" The article provides an in-depth look at the benefits and considerations associated with revocable living trusts, an increasingly popular estate planning tool. Atlanta estate planning attorney Trace Brooks explores the circumstances under which a revocable living trust can be a valuable addition to an individual's estate

All 5 Releases


More Releases for Neuroendocrine

Neuroendocrine Tumor Treatment Market – Forecast to 2026
According to a new market research report published by Global Market Estimates, the Global Neuroendocrine Tumor Treatment Market is projected to grow from USD 1.8 billion in 2021 to USD 2.1 billion by 2026 at a CAGR value of 5.7% between 2021 to 2026. High prevalence of neuropsychiatric malignancy, awareness regarding early cancer diagnosis, and an increasing number of government initiatives, the neuroendocrine tumor therapy market is expected to rise
Neuroendocrine Carcinoma Market Size - Forecasts to 2026
The findings reviewed by GME stated that the Global Neuroendocrine Carcinoma Market will expand with a CAGR value of 10.6 percent from 2021 to 2026. Owing to a rise in the prevalence of neuroendocrine tumors (NETs) across the globe, the global neuroendocrine carcinoma market will grow rapidly during 2021-2026 forecast period. Browse the Report @ https://www.globalmarketestimates.com/market-report/global-neuroendocrine-carcinoma-market-3109 By Site (Gastrointestinal, Lung, Brain, Pancreas, and Others), By Therapy (Surgery, Radiation Therapy, and Chemotherapy), By
Neuroendocrine Cancer Market: Rising Prevalence of Neuroendocrine Cancer and Gro …
The market report titled ‘Global Neuroendocrine Cancer Market - Size, Share and Forecast (2019 - 2026)’ produced by DataM Intelligence analyses the industry dynamics in this competitive space to provide a comprehensive analysis of the market opportunities. Neuroendocrine Cancer Market Segmentation Analysis Total Neuroendocrine Cancer Studies: 2499 By Drug Type Everolimus Sunitinib Malate Lanreotide Octreotide Others Sunitinib (Sutent) and Everolimus (Afinitor) are two major targeted drugs that are being used for the treatment of
Neuroendocrine Carcinoma Market Analysis & Key Trends 2020
A neuroendocrine tumor is a kind of tumor that begins in the hormone producing cells of the neuroendocrine system that is made up of the endocrine system and nervous system. Hormones producing neuroendocrine cells have a structure similar to neurons and produce hormones like endocrine cells. These cells are found throughout the body in organs such as intestines, kidneys, lungs and stomach and perform functions such as controlling the speed
Neuroendocrine Tumors Pipeline Review H1 2017
Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Neuroendocrine Tumors - Pipeline Review, H1 2017, provides an overview of the Neuroendocrine Tumors (Oncology) pipeline landscape. Neuroendocrine tumor begins in the hormone-producing cells of the body's neuroendocrine system, which is made up of cells that are a cross between traditional endocrine cells (or hormone-producing cells) and nerve cells. Symptom includes hyperglycemia, diarrhea, loss of appetite/weight loss, thickening or lump in any part
Neuroendocrine Tumors Pipeline Review H1 2017
Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Neuroendocrine Tumors - Pipeline Review, H1 2017, provides an overview of the Neuroendocrine Tumors (Oncology) pipeline landscape. Neuroendocrine tumor begins in the hormone-producing cells of the body's neuroendocrine system, which is made up of cells that are a cross between traditional endocrine cells (or hormone-producing cells) and nerve cells. Symptom includes hyperglycemia, diarrhea, loss of appetite/weight loss, thickening or lump in any part